Mechanism of drug resistance due to N88S in CRF01_AE HIV-1 protease, analyzed by molecular dynamics simulations.

Nelfinavir (NFV) is a currently available HIV-1 protease (PR) inhibitor. Patients in whom NFV treatment has failed predominantly carry D30N mutants of HIV-1 PRs if they have been infected with the subtype B virus. In contrast, N88S mutants of HIV-1 PRs predominantly emerge in patients in whom NFV treatment has failed and who carry the CRF01_AE virus. Both D30N and N88S confer resistance against NFV. However, it remains unclear why the nonactive site mutation N88S confers resistance against NFV. In this study, we examined the resistance mechanism through computational simulations. The simulations suggested that despite the nonactive site mutation, N88S causes NFV resistance by reducing interactions between PR and NFV. We also investigated why the emergence rates of D30N and N88S differ between subtype B and CRF01_AE HIV-1. The simulations suggested that polymorphisms of CRF01_AE PR are involved in the emergence rate of the drug-resistant mutants.

[1]  S. Rick,et al.  Molecular mechanisms of resistance: Free energy calculations of mutation effects on inhibitor binding to HIV‐1 protease , 1998, Protein science : a publication of the Protein Society.

[2]  J. Louis,et al.  Structural and kinetic analysis of drug resistant mutants of HIV-1 protease. , 2000, European journal of biochemistry.

[3]  Junmei Wang,et al.  Development and testing of a general amber force field , 2004, J. Comput. Chem..

[4]  Celia A. Schiffer,et al.  Structural and Thermodynamic Basis for the Binding of TMC114, a Next-Generation Human Immunodeficiency Virus Type 1 Protease Inhibitor , 2004, Journal of Virology.

[5]  Brendan Larder,et al.  Interference between D30N and L90M in Selection and Development of Protease Inhibitor-Resistant Human Immunodeficiency Virus Type 1 , 2002, Antimicrobial Agents and Chemotherapy.

[6]  E. Freire,et al.  Multidrug resistance to HIV-1 protease inhibition requires cooperative coupling between distal mutations. , 2003, Biochemistry.

[7]  D J Hu,et al.  Protease sequences from HIV-1 group M subtypes A–H reveal distinct amino acid mutation patterns associated with protease resistance in protease inhibitor-naive individuals worldwide , 2000, AIDS.

[8]  S. Pazhanisamy,et al.  Weak binding of VX-478 to human plasma proteins and implications for anti-human immunodeficiency virus therapy. , 1995, The Journal of infectious diseases.

[9]  Remco,et al.  pol gene diversity of five human immunodeficiency virus type 1 subtypes: evidence for naturally occurring mutations that contribute to drug resistance, limited recombination patterns, and common ancestry for subtypes B and D , 1997, Journal of virology.

[10]  I B Duncan,et al.  Rational design of peptide-based HIV proteinase inhibitors. , 1990, Science.

[11]  Irene T Weber,et al.  Crystal structures of HIV protease V82A and L90M mutants reveal changes in the indinavir-binding site. , 2004, European journal of biochemistry.

[12]  P. Darke,et al.  L-735,524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[13]  C. Schiffer,et al.  Viability of a Drug-Resistant Human Immunodeficiency Virus Type 1 Protease Variant: Structural Insights for Better Antiviral Therapy , 2003, Journal of Virology.

[14]  Brendan A. Larder,et al.  Tipranavir inhibits broadly protease inhibitor-resistant HIV-1 clinical samples , 2000, AIDS.

[15]  Wei Zhang,et al.  A point‐charge force field for molecular mechanics simulations of proteins based on condensed‐phase quantum mechanical calculations , 2003, J. Comput. Chem..

[16]  S. Vasavanonda,et al.  ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[17]  Peter A. Kollman,et al.  FREE ENERGY CALCULATIONS : APPLICATIONS TO CHEMICAL AND BIOCHEMICAL PHENOMENA , 1993 .

[18]  Irene T Weber,et al.  Combining mutations in HIV‐1 protease to understand mechanisms of resistance , 2002, Proteins.

[19]  David A. Stock,et al.  BMS-232632, a Highly Potent Human Immunodeficiency Virus Protease Inhibitor That Can Be Used in Combination with Other Available Antiretroviral Agents , 2000, Antimicrobial Agents and Chemotherapy.

[20]  Masayuki Hata,et al.  Hydrolysis Mechanism of the Phenylalanine−Proline Peptide Bond Specific to HIV-1 Protease: Investigation by the ab Initio Molecular Orbital Method , 1999 .

[21]  P. Kollman,et al.  Calculating structures and free energies of complex molecules: combining molecular mechanics and continuum models. , 2000, Accounts of chemical research.

[22]  Martine Peeters,et al.  Genetic Diversity of Protease and Reverse Transcriptase Sequences in Non-Subtype-B Human Immunodeficiency Virus Type 1 Strains: Evidence of Many Minor Drug Resistance Mutations in Treatment-Naive Patients , 2000, Journal of Clinical Microbiology.

[23]  Jindrich Hasek,et al.  HIV-1 protease mutations and inhibitor modifications monitored on a series of complexes. Structural basis for the effect of the A71V mutation on the active site. , 2006, Journal of medicinal chemistry.

[24]  J. Mccammon,et al.  HIV‐1 protease molecular dynamics of a wild‐type and of the V82F/I84V mutant: Possible contributions to drug resistance and a potential new target site for drugs , 2004, Protein science : a publication of the Protein Society.

[25]  Irene T. Weber,et al.  Novel bis-Tetrahydrofuranylurethane-Containing Nonpeptidic Protease Inhibitor (PI) UIC-94017 (TMC114) with Potent Activity against Multi-PI-Resistant Human Immunodeficiency Virus In Vitro , 2003, Antimicrobial Agents and Chemotherapy.

[26]  Dale J. Kempf,et al.  In Vitro Selection and Characterization of Human Immunodeficiency Virus Type 1 Variants with Increased Resistance to ABT-378, a Novel Protease Inhibitor , 1998, Journal of Virology.

[27]  Supot Hannongbua,et al.  Insights into saquinavir resistance in the G48V HIV-1 protease: quantum calculations and molecular dynamic simulations. , 2005, Biophysical journal.

[28]  Ursula Rothlisberger,et al.  Drug resistance in HIV‐1 protease: Flexibility‐assisted mechanism of compensatory mutations , 2002, Protein science : a publication of the Protein Society.

[29]  M. Hatada,et al.  Novel binding mode of highly potent HIV-proteinase inhibitors incorporating the (R)-hydroxyethylamine isostere. , 1991, Journal of medicinal chemistry.

[30]  D. R. Kuritzkes,et al.  Genotypic and Phenotypic Characterization of Human Immunodeficiency Virus Type 1 Variants Isolated from Patients Treated with the Protease Inhibitor Nelfinavir , 1998, Antimicrobial Agents and Chemotherapy.

[31]  L Hong,et al.  Crystal structure of an in vivo HIV‐1 protease mutant in complex with saquinavir: Insights into the mechanisms of drug resistance , 2000, Protein science : a publication of the Protein Society.

[32]  Celia A Schiffer,et al.  Lack of synergy for inhibitors targeting a multi‐drug‐resistant HIV‐1 protease , 2002, Protein science : a publication of the Protein Society.

[33]  P. Pascutti,et al.  Molecular dynamics simulations applied to the study of subtypes of HIV-1 protease common to Brazil, Africa, and Asia , 2007, Cell Biochemistry and Biophysics.

[34]  G. Ciccotti,et al.  Numerical Integration of the Cartesian Equations of Motion of a System with Constraints: Molecular Dynamics of n-Alkanes , 1977 .

[35]  J F Davies,et al.  Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease. , 1997, Journal of medicinal chemistry.

[36]  A. Velázquez‐Campoy,et al.  Protease inhibition in African subtypes of HIV-1. , 2003, AIDS reviews.

[37]  D. Case,et al.  Exploring protein native states and large‐scale conformational changes with a modified generalized born model , 2004, Proteins.

[38]  Deenan Pillay,et al.  Update of the drug resistance mutations in HIV-1: Fall 2006. , 2006, Topics in HIV medicine : a publication of the International AIDS Society, USA.

[39]  P A Kollman,et al.  Free energy calculations on dimer stability of the HIV protease using molecular dynamics and a continuum solvent model. , 2000, Journal of molecular biology.

[40]  D. Ho,et al.  Antiviral and resistance studies of AG1343, an orally bioavailable inhibitor of human immunodeficiency virus protease , 1996, Antimicrobial agents and chemotherapy.

[41]  M Karplus,et al.  Relation between sequence and structure of HIV-1 protease inhibitor complexes: a model system for the analysis of protein flexibility. , 2002, Journal of molecular biology.

[42]  J S Mills,et al.  Antiviral properties of Ro 31-8959, an inhibitor of human immunodeficiency virus (HIV) proteinase. , 1991, Antiviral research.

[43]  Maureen M Goodenow,et al.  Comparing the accumulation of active- and nonactive-site mutations in the HIV-1 protease. , 2004, Biochemistry.

[44]  Y. Takebe,et al.  Evolution and Biological Characterization of Human Immunodeficiency Virus Type 1 Subtype E gp120 V3 Sequences following Horizontal and Vertical Virus Transmission in a Single Family , 1999, Journal of Virology.

[45]  R. Swanstrom,et al.  Nelfinavir-Resistant, Amprenavir-Hypersusceptible Strains of Human Immunodeficiency Virus Type 1 Carrying an N88S Mutation in Protease Have Reduced Infectivity, Reduced Replication Capacity, and Reduced Fitness and Process the Gag Polyprotein Precursor Aberrantly , 2002, Journal of Virology.

[46]  J. Louis,et al.  Structural implications of drug‐resistant mutants of HIV‐1 protease: High‐resolution crystal structures of the mutant protease/substrate analogue complexes , 2001, Proteins.

[47]  W. L. Jorgensen,et al.  Comparison of simple potential functions for simulating liquid water , 1983 .

[48]  Christos J. Petropoulos,et al.  A Mutation in Human Immunodeficiency Virus Type 1 Protease, N88S, That Causes In Vitro Hypersensitivity to Amprenavir , 2000, Journal of Virology.

[49]  Maureen M Goodenow,et al.  Analysis of HIV-1 CRF_01 A/E protease inhibitor resistance: structural determinants for maintaining sensitivity and developing resistance to atazanavir. , 2006, Biochemistry.

[50]  Thomas Klimkait,et al.  Unusual binding mode of an HIV-1 protease inhibitor explains its potency against multi-drug-resistant virus strains. , 2002, Journal of molecular biology.

[51]  L J Davis,et al.  Active human immunodeficiency virus protease is required for viral infectivity. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[52]  Peter A. Kollman,et al.  Application of the multimolecule and multiconformational RESP methodology to biopolymers: Charge derivation for DNA, RNA, and proteins , 1995, J. Comput. Chem..

[53]  Masayuki Hata,et al.  Computational simulations of HIV-1 proteases--multi-drug resistance due to nonactive site mutation L90M. , 2006, Journal of the American Chemical Society.

[54]  D. Richman,et al.  2022 update of the drug resistance mutations in HIV-1. , 2022, Topics in antiviral medicine.

[55]  Kaneo Yamada,et al.  Patterns of point mutations associated with antiretroviral drug treatment failure in CRF01_AE (subtype E) infection differ from subtype B infection. , 2003, Journal of acquired immune deficiency syndromes.

[56]  Masayuki Hata,et al.  Resistant mechanism against nelfinavir of human immunodeficiency virus type 1 proteases. , 2005 .

[57]  Zehava Grossman,et al.  Genotypic variation of HIV-1 reverse transcriptase and protease: comparative analysis of clade C and clade B , 2001, AIDS.

[58]  Celia A. Schiffer,et al.  Structural Basis for Coevolution of a Human Immunodeficiency Virus Type 1 Nucleocapsid-p1 Cleavage Site with a V82A Drug-Resistant Mutation in Viral Protease , 2004, Journal of Virology.

[59]  Maureen M Goodenow,et al.  Secondary mutations M36I and A71V in the human immunodeficiency virus type 1 protease can provide an advantage for the emergence of the primary mutation D30N. , 2003, Biochemistry.

[60]  P. Kollman,et al.  Combined molecular mechanical and continuum solvent approach (MM-PBSA/GBSA) to predict ligand binding , 2000 .

[61]  A. Velázquez‐Campoy,et al.  Catalytic efficiency and vitality of HIV-1 proteases from African viral subtypes , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[62]  Heinrich Sticht,et al.  Insights into amprenavir resistance in E35D HIV-1 protease mutation from molecular dynamics and binding free-energy calculations , 2007, Journal of molecular modeling.

[63]  P. Kollman,et al.  Continuum Solvent Studies of the Stability of DNA, RNA, and Phosphoramidate−DNA Helices , 1998 .